Eli Lilly Turns to Tau Proteins with AC Immune Alzheimer’s Deal

By Subham Nandi

Pharma Deals Review: Vol 2018 Issue 12 (Table of Contents)

Published: 28 Dec-2018

DOI: 10.3833/pdr.v2018.i12.2389     ISSN: 1756-7874

Section: Research & Development



Despite several high-profile setbacks, Eli Lilly has agreed to in-license AC Immune’s tau aggregation inhibitors for the treatment of Alzheimer’s disease and other neurodegenerative diseases for a total potential deal value of CHF1840 M (US$1858...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details